Virtual Library

Start Your Search

Taewon Jang

Author of

  • +

    P1.04 - Immunooncology (Not CME Accredited Session) (ID 936)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.04-18 - PD-L1 Expression and its Correlation with Tumor TNM Stage in Patients with Non-Small Cell Lung Cancer   (ID 13121)

      16:45 - 18:00  |  Presenting Author(s): Taewon Jang

      • Abstract


      Immunotherapy has now become a standard therapy of lung cancer treatment. Programmed death ligand (PD-L) 1 expression has provided a predictive biomarker for anti-PD-1/PD-L1 therapy. However, the relationship between the expression of PD-L1 and the clinical and pathologic features were still unclear. The purpose of this study was to investigate the clinical factors affecting the expression of PD-L1 and the concordance of the DAKO assay with the Ventana assay.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We evaluated in 178 non-small-cell lung cancer patients and assessed PD-L1 expression by immunohistochemistry after staining them with antibody 22C3 (Dako) or SP263 (Ventana). Clinical features were acquired from the electrical medical records, retrospectively. We analyzed the relationship between PD-L1 expression and clinicopathological characteristics.

      4c3880bb027f159e801041b1021e88e8 Result

      One hundred fifty four patients were available for analysis. There were 130 cases which both tests were performed. Mean age was 66.7 years-old. Male patients were 70%, and adenocarcinoma was 68%. Stages were stage I 15.6%, II 7.1%, III 28.6%, and IV 48.7% respectively. In using the 22C3 antibody, PD-L1 expression in Tumor proportion score (TPS) ≥ 50% was 27.7%, and 52.3% in TPS ≥ 1%. PD-L1 expression rate in man was higher than woman (37,6 % vs 16,7%, P=0.028). In the sp263 antibody, PD-L1 expression rate (TPS ≥10%) was 52.9%, and 68.8% in TPS ≥ 1%. Age, primary tumor, regional lymph node, distant metastasis and stage grouping were not statistical different between patients with and without PD-L1 expression. All patients (n=36) with TPS ≥ 50% in the 22c3 test were found to have TPS ≥ 10% in the sp263 test.

      8eea62084ca7e541d918e823422bd82e Conclusion

      There were no specific predictable factor in PD-L1 expression except male factor. But, we suggest that further study will be needed by adding other factors and more patients.